UFP Technologies, Inc.
UFPTUFP Technologies, Inc.'s price has outrun its earnings. +47.8% in a year against EPS +15.4% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +47.8% in a year while annual EPS moved +15.4% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (5 weeks in) while the P/E sits at the 82nd percentile of its own 4-year range. Underneath, the last four quarters read mixed — profit +0.0% year on year, and 118% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
UFP Technologies, Inc. trades at $335, in a confirmed uptrend and 5 weeks into that stage. That is +48.0% against its own 200-day average. It sits at 100% of a 52-week range of $189 to $335. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 9 straight weeks.
Today the stock is in a confirmed uptrend — week 5 of stage 2. At $335 it trades +48.0% versus its 200-day average and sits at 100% of its 52-week range ($189–$335).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +1,343% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 9 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
UFP Technologies, Inc. trades at 36.2× P/E, at the pricey end of its own range (82nd percentile). Its long-run median P/E is 28.6×, measured across 4.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 36.2× is at the pricey end of its own range (82nd percentile), against a long-run median of 28.6× measured over 4.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +15.4% against a +47.8% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +22.4%/yr price move, ~+10.7%/yr came from earnings growth and ~+11.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
UFP Technologies, Inc. reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +44.4% at its peak to +9.1% but is still expanding, ROCE slipping at 13.9%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +20.0% | +19.7% | — | — |
| Profit | +16.7% | +20.5% | — | — |
| EPS | +15.4% | +17.1% | — | — |
| Stock price | +47.8% | +22.4% | +37.4% | +30.2% |
4-Factor Sector Score
56.3/100 — rank 4 of 30 in Medical Devices · 81% evidence confidence
UFP Technologies, Inc. scores 56.3 out of 100 against the 30 companies it is compared with in Medical Devices, ranking 4. Price leads the evidence: RS versus the benchmark is 34.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 15.7 + 15.2 + 6.5 + 18.9 = 56.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
UFP Technologies, Inc. reported $0.1 B of revenue in the Mar 26 quarter, +0.0% year on year. Over 4 years it has compounded at 30.0% a year. The last full year, FY25, came in at $0.6 B. The last four reported quarters add to $0.6 B.
FY25 revenue came in at $0.6 B (+20.0% on the year), capping 4 years at 30.0% compound. The latest quarter (Mar 26) printed $0.1 B, +0.0% year on year.
Pace check: the last four quarters averaged +10.9% growth against the decade's 30.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +9.1% over the last 4 quarters against +21.0%/yr over the last 8 — rolling over; TTM profit +14.3% vs +41.4%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
UFP Technologies, Inc.'s operating margin is 13.3% in the Mar 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 9.5% to 17.1%. The current quarter sits inside that band.
The latest quarter's operating margin is 13.3%, +0.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 9.5%–17.1%.
Why the margin moved: operating margin went +0.0 pp year on year while gross margin went +0.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
UFP Technologies, Inc. earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.1 B. The 4-year compound rate is 36.8%. That is 13.3% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.
Mar 26 profit was $0.0 B, +0.0% year on year. On the full year, FY25 printed $0.1 B (+16.7%), and the 4-year compound rate is 36.8%.
🚨 Why profit moved: revenue contributed +0.0% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +25.0% vs revenue +10.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 118% of UFP Technologies, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.1 B of operating cash against $0.1 B of profit. After $0.0 B of capital spending, $0.1 B was left as free cash.
FY25: operating cash of $0.1 B against reported profit of $0.1 B, leaving free cash of $0.1 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 118% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
UFP Technologies, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
UFP Technologies, Inc. earns a ROE of 17% in FY25. That is up from a trough of 11% in FY21. Return on invested capital clears the cost of that capital by +3.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 11.7% net margin on 0.91× asset turns.
FY25 ROE is 17%, recovered from a FY21 trough of 11% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 11.7% net margin × 0.91× asset turns × 1.57× balance-sheet leverage ≈ 16.7% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 13.7% − 9.9% = a +3.8 pp spread. The 9.9% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
Dividend
UFP Technologies, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
UFP Technologies, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
UFP Technologies, Inc. carries total debt of $0.2 B against shareholder equity of $0.4 B as of Mar 26, a debt-to-equity of 0.36. On the annual view that ratio went from 0.42 in FY21 to 0.36 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $0.2 B against shareholder equity of $0.4 B — a debt-to-equity of 0.36. On the annual view, debt-to-equity went from 0.42 (FY21) to 0.36 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
16.7% of UFP Technologies, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 5.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 16.7% of the float is sold short, and at typical trading volumes it would take about 5.5 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
UFP Technologies, Inc.: the Z-score reads 6.80. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 6.80 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 6.80.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1DexCom, Inc.DXCM | 66.1/100Thin evidence · provisional58% evidence | BREAKING OUT | 22.9/35 Revenue — · PAT — · OPM change 8.5 pp 45% evidence | 16.8/25 ROCE 7.8% · OPM 21.4% 76% evidence | 9.9/20 P/E 26.6× · PEG — 15% evidence | 16.5/20 RS sector 6.5% · RS bench 12.9% · 1Y 10.2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 16.8 + 9.9 + 16.5 = 66.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Globus Medical, Inc.GMED | 60.3/100Mixed-positive evidence81% evidence | ASLEEP | 25.6/35 Revenue 23.5% · PAT 100% · OPM change 3.6 pp 83% evidence | 14.8/25 ROCE 3.2% · OPM 19.8% 76% evidence | 15.2/20 P/E 20× · PEG 0.85 65% evidence | 4.7/20 RS sector -13.1% · RS bench -8.3% · 1Y 39%0 of 12 weeks ahead 100% evidence |
| Exact sum: 25.6 + 14.8 + 15.2 + 4.7 = 60.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -13.1% and the one-year return is 39%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3LivaNova PLCLIVN | 57.8/100Mixed-positive evidence64% evidence | BREAKING OUT | 24.7/35 Revenue 12.4% · PAT — · OPM change 109.8 pp 62% evidence | 11.1/25 ROCE 2.3% · OPM 11.4% 76% evidence | 9.5/20 P/E 32.6× · PEG — 15% evidence | 12.5/20 RS sector 11.8% · RS bench 18.6% · 1Y 74.7%9 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 11.1 + 9.5 + 12.5 = 57.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4UFP Technologies, Inc.this pageUFPT | 56.3/100Mixed-positive evidence81% evidence | BREAKING OUT | 15.7/35 Revenue 11.3% · PAT 7.9% · OPM change -0.4 pp 83% evidence | 15.2/25 ROCE 4% · OPM 15.2% 76% evidence | 6.5/20 P/E 22× · PEG 2.9 65% evidence | 18.9/20 RS sector 27.1% · RS bench 34.5% · 1Y 62.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 15.2 + 6.5 + 18.9 = 56.3 · Decision use: Price leads the evidence: RS versus the benchmark is 34.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 5STERIS plcSTE | 56.1/100Mixed-positive evidence81% evidence | TURNING | 22.3/35 Revenue 8.9% · PAT 27.4% · OPM change 5.3 pp 83% evidence | 14.8/25 ROCE 3.4% · OPM 19.9% 76% evidence | 12.8/20 P/E 27.9× · PEG 1 65% evidence | 6.2/20 RS sector -16.8% · RS bench -12% · 1Y -4.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 22.3 + 14.8 + 12.8 + 6.2 = 56.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Edwards Lifesciences CorporationEW | 55.6/100Thin evidence · provisional58% evidence | TURNING | 22.1/35 Revenue — · PAT — · OPM change 1.1 pp 45% evidence | 17.9/25 ROCE 8.5% · OPM 29% 76% evidence | 9.0/20 P/E 52× · PEG — 15% evidence | 6.6/20 RS sector -8.3% · RS bench -2.8% · 1Y 14.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 17.9 + 9 + 6.6 = 55.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Establishment Labs Holdings Inc.ESTA | 52.5/100Mixed-positive evidence61% evidence | BREAKING OUT | 25.0/35 Revenue 35.3% · PAT — · OPM change 30.1 pp 62% evidence | 3.6/25 ROCE -2.4% · OPM -10.9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.9/20 RS sector 22.8% · RS bench 29.8% · 1Y 171.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 25 + 3.6 + 10 + 13.9 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Butterfly Network, Inc.BFLY | 52.5/100Thin evidence · provisional55% evidence | LEADER | 19.4/35 Revenue — · PAT — · OPM change 34.7 pp 45% evidence | 3.1/25 ROCE -5.5% · OPM -52.3% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 20.0/20 RS sector 88.6% · RS bench 99.8% · 1Y 562.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 3.1 + 10 + 20 = 52.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Stryker CorporationSYK | 52.3/100Thin evidence · provisional58% evidence | TURNING | 19.5/35 Revenue — · PAT — · OPM change 1.2 pp 45% evidence | 15.6/25 ROCE 4.1% · OPM 15.5% 76% evidence | 9.4/20 P/E 32.6× · PEG — 15% evidence | 7.8/20 RS sector -18.8% · RS bench -14% · 1Y -11%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 15.6 + 9.4 + 7.8 = 52.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Boston Scientific CorporationBSX | 52.1/100Thin evidence · provisional58% evidence | BASING | 22.2/35 Revenue — · PAT — · OPM change 1.4 pp 45% evidence | 17.0/25 ROCE 6.5% · OPM 21.2% 76% evidence | 11.2/20 P/E 17.3× · PEG — 15% evidence | 1.7/20 RS sector -46.8% · RS bench -43.8% · 1Y -52.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 17 + 11.2 + 1.7 = 52.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Integer Holdings CorporationITGR | 51.9/100Thin evidence · provisional58% evidence | TURNING | 13.3/35 Revenue — · PAT — · OPM change -5.3 pp 45% evidence | 10.1/25 ROCE 1% · OPM 7.2% 76% evidence | 10.8/20 P/E 21.6× · PEG — 15% evidence | 17.7/20 RS sector 18.1% · RS bench 25.5% · 1Y 17.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 10.1 + 10.8 + 17.7 = 51.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Zimmer Biomet Holdings, Inc.ZBH | 48.7/100Mixed-negative evidence81% evidence | TURNING | 16.9/35 Revenue 9.2% · PAT -16.9% · OPM change 2.6 pp 83% evidence | 12.1/25 ROCE 1.9% · OPM 17.9% 76% evidence | 12.3/20 P/E 23.5× · PEG 1.09 65% evidence | 7.4/20 RS sector -13.2% · RS bench -8% · 1Y -3.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 12.1 + 12.3 + 7.4 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Glaukos CorporationGKOS | 48.6/100Thin evidence · provisional55% evidence | BREAKING OUT | 18.6/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence | 4.2/25 ROCE -2% · OPM -13.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.8/20 RS sector 28% · RS bench 35.5% · 1Y 101.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 4.2 + 10 + 15.8 = 48.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Insulet CorporationPODD | 47.7/100Mixed-negative evidence71% evidence | TURNING | 19.0/35 Revenue 31.9% · PAT -24.6% · OPM change 0.4 pp 83% evidence | 14.9/25 ROCE 4.6% · OPM 16% 76% evidence | 9.2/20 P/E 48.8× · PEG — 15% evidence | 4.6/20 RS sector -43.2% · RS bench -40% · 1Y -45.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 14.9 + 9.2 + 4.6 = 47.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Neogen CorporationNEOG | 46.7/100Thin evidence · provisional58% evidence | TURNING | 18.0/35 Revenue — · PAT — · OPM change -4 pp 45% evidence | 6.3/25 ROCE 0.1% · OPM -1.6% 76% evidence | 8.5/20 P/E 1719× · PEG — 15% evidence | 13.9/20 RS sector 22.2% · RS bench 29.2% · 1Y 132.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 6.3 + 8.5 + 13.9 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16GE HealthCare Technologies Inc.GEHC | 45.4/100Thin evidence · provisional58% evidence | TURNING | 15.3/35 Revenue — · PAT — · OPM change -3.2 pp 45% evidence | 13.4/25 ROCE 2.7% · OPM 10% 76% evidence | 11.4/20 P/E 14.7× · PEG — 15% evidence | 5.3/20 RS sector -18.8% · RS bench -14.2% · 1Y -2.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.3 + 13.4 + 11.4 + 5.3 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Haemonetics CorporationHAE | 44.8/100Mixed-negative evidence81% evidence | BREAKING OUT | 5.4/35 Revenue -2.1% · PAT -41.3% · OPM change -28.2 pp 83% evidence | 7.0/25 ROCE -1.2% · OPM -6.6% 76% evidence | 15.1/20 P/E 26.4× · PEG 0.52 65% evidence | 17.3/20 RS sector 10.9% · RS bench 17% · 1Y 58.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 5.4 + 7 + 15.1 + 17.3 = 44.8 · Decision use: Price leads the evidence: RS versus the benchmark is 17%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 18Koninklijke Philips N.V.PHG | 44.3/100Thin evidence · provisional58% evidence | BASING | 19.4/35 Revenue — · PAT — · OPM change 2.4 pp 45% evidence | 10.9/25 ROCE 3.2% · OPM 6.2% 76% evidence | 11.0/20 P/E 20.5× · PEG — 15% evidence | 3.0/20 RS sector -19.4% · RS bench -14.6% · 1Y -1.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.4 + 10.9 + 11 + 3 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Medtronic plcMDT | 43.1/100Mixed-negative evidence85% evidence | TURNING | 18.1/35 Revenue 8.4% · PAT 3.1% · OPM change 3 pp 95% evidence | 14.3/25 ROCE 2.3% · OPM 19.1% 76% evidence | 5.6/20 P/E 22.3× · PEG 3.08 65% evidence | 5.1/20 RS sector -19.6% · RS bench -15% · 1Y -7.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 14.3 + 5.6 + 5.1 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20TransMedics Group, Inc.TMDX | 41.6/100Mixed-negative evidence71% evidence | TURNING | 16.7/35 Revenue 30.1% · PAT 100% · OPM change -11.5 pp 83% evidence | 8.7/25 ROCE 1.3% · OPM 7.6% 76% evidence | 10.5/20 P/E 22.6× · PEG — 15% evidence | 5.7/20 RS sector -37.4% · RS bench -34.1% · 1Y -29.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.7 + 8.7 + 10.5 + 5.7 = 41.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Axogen, Inc.AXGN | 40.8/100Thin evidence · provisional55% evidence | FADING | 12.2/35 Revenue — · PAT — · OPM change -1.2 pp 45% evidence | 5.6/25 ROCE -0.9% · OPM -4.6% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 13.0/20 RS sector 25.1% · RS bench 32.6% · 1Y 230.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 12.2 + 5.6 + 10 + 13 = 40.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22iRhythm Holdings, Inc.IRTC | 40.3/100Mixed-negative evidence61% evidence | TURNING | 22.9/35 Revenue 27.3% · PAT — · OPM change 12.4 pp 62% evidence | 4.6/25 ROCE -1.9% · OPM -8.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.8/20 RS sector -26.9% · RS bench -22.6% · 1Y -19.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 4.6 + 10 + 2.8 = 40.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -26.9% and the one-year return is -19.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 23Inspire Medical Systems, Inc.INSP | 40.0/100Mixed-negative evidence75% evidence | TURNING | 17.3/35 Revenue 9.1% · PAT 98.5% · OPM change 0.2 pp 83% evidence | 6.1/25 ROCE -0.2% · OPM -0.5% 76% evidence | 12.3/20 P/E 11.5× · PEG 1.35 65% evidence | 4.3/20 RS sector -23.1% · RS bench -19.2% · 1Y -19%1 of 12 weeks ahead 70% evidence |
| Exact sum: 17.3 + 6.1 + 12.3 + 4.3 = 40 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24NovoCure LimitedNVCR | 39.4/100Thin evidence · provisional55% evidence | FADING | 16.0/35 Revenue — · PAT — · OPM change -14.3 pp 45% evidence | 3.8/25 ROCE -2% · OPM -38.7% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.6/20 RS sector 0.9% · RS bench 7.4% · 1Y 46.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 3.8 + 10 + 9.6 = 39.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Penumbra, Inc.PEN | 39.0/100Thin evidence · provisional58% evidence | ASLEEP | 14.0/35 Revenue — · PAT — · OPM change -2.2 pp 45% evidence | 11.5/25 ROCE 2.5% · OPM 10.2% 76% evidence | 8.6/20 P/E 134.4× · PEG — 15% evidence | 4.9/20 RS sector -10.6% · RS bench -5.4% · 1Y 34.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 11.5 + 8.6 + 4.9 = 39 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Abbott LaboratoriesABT | 35.2/100Mixed-negative evidence85% evidence | TURNING | 7.9/35 Revenue 8.1% · PAT -61.2% · OPM change -5 pp 95% evidence | 12.8/25 ROCE 2.1% · OPM 13.4% 76% evidence | 7.3/20 P/E 29.4× · PEG 2.31 65% evidence | 7.2/20 RS sector -21% · RS bench -16.4% · 1Y -21.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 12.8 + 7.3 + 7.2 = 35.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27Bruker CorporationBRKR | 34.5/100Adverse evidence71% evidence | LEADER | 8.0/35 Revenue 0.3% · PAT -112.7% · OPM change -2.8 pp 83% evidence | 9.2/25 ROCE 0.2% · OPM 1.2% 76% evidence | 8.8/20 P/E 79.2× · PEG — 15% evidence | 8.5/20 RS sector -2.2% · RS bench 3.6% · 1Y 65.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 8 + 9.2 + 8.8 + 8.5 = 34.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Enovis CorporationENOV | 46.0/100Thin evidence · provisional50% evidence | TURNING | 19.6/35 Revenue — · PAT — · OPM change 9.5 pp 39% evidence | 6.5/25 ROCE 0.2% · OPM 1.1% 76% evidence | 8.9/20 P/E 58.3× · PEG — 15% evidence | 11.0/20 RS sector -2% · RS bench 4% · 1Y 8.5%3 of 12 weeks ahead 70% evidence |
| Exact sum: 19.6 + 6.5 + 8.9 + 11 = 46 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Smith & Nephew plcSNN | 42.9/100Thin evidence · provisional38% evidence | BASING | 17.5/35 Revenue — · PAT — · OPM change — 9% evidence | 12.4/25 ROCE 2.1% · OPM — 46% evidence | 10.3/20 P/E 22.9× · PEG — 15% evidence | 2.7/20 RS sector -23% · RS bench -18.4% · 1Y -15.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 12.4 + 10.3 + 2.7 = 42.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 30Bio-Rad Laboratories, Inc.BIO-B | 41.8/100Thin evidence · provisional44% evidence | TURNING | 14.8/35 Revenue 1.9% · PAT — · OPM change 1.8 pp 62% evidence | 7.7/25 ROCE 0.4% · OPM 5.8% 76% evidence | 9.3/20 P/E 45.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —1 of 4 weeks ahead 0% evidence |
| Exact sum: 14.8 + 7.7 + 9.3 + 10 = 41.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is UFP Technologies, Inc.'s stock price today?
UFP Technologies, Inc. trades at $335, +47.8% over the past year. The company is valued at $3.0 B. The stock sits at 100% of its 52-week range of $189–$335, +48.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 5 weeks in. — as of 5 August 2026.
What were UFP Technologies, Inc.'s latest quarterly results?
UFP Technologies, Inc. reported revenue of $0.1 B and net profit of $0.0 B for the Mar 26 quarter. Revenue rose 0.0% and profit rose 0.0% year on year. Earnings per share were $2.24. The operating margin was 13.3%, 0.0 pp higher than a year earlier. — as of 5 August 2026.
What is UFP Technologies, Inc.'s revenue?
UFP Technologies, Inc. reported revenue of $0.1 B in the Mar 26 quarter, +0.0% year on year. For the full FY25 fiscal year, revenue was $0.6 B (+20.0%). Over the last 4 years revenue compounded at 30.0% a year. — as of 5 August 2026.
What is UFP Technologies, Inc.'s profit?
UFP Technologies, Inc. earned $0.0 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.1 B. The operating margin ran 13.3% in the latest quarter. — as of 5 August 2026.
What is UFP Technologies, Inc.'s market cap?
UFP Technologies, Inc.'s market capitalisation is $3.0 B at a stock price of $335. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is UFP Technologies, Inc.'s P/E ratio?
UFP Technologies, Inc. trades at a P/E of 36.2×, at the 82nd percentile of its own 4-year range, against a long-run median of 28.6×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does UFP Technologies, Inc. pay a dividend?
No — UFP Technologies, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is UFP Technologies, Inc. overvalued?
On its own history, UFP Technologies, Inc. looks expensive against its own history: its P/E of 36.2× sits at the 82nd percentile of its 4-year range (long-run median 28.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is UFP Technologies, Inc. growing?
The picture is mixed for UFP Technologies, Inc.: latest-quarter revenue +0.0% year on year, profit +0.0%, and the margin +0.0 pp at 13.3%. The 4-year compound rates are 30.0% (revenue) and 36.8% (profit). The earnings engine currently reads: mixed — as of 5 August 2026.
How is UFP Technologies, Inc. performing?
UFP Technologies, Inc. is in a confirmed uptrend, 5 weeks in. Its latest quarter's revenue rose 0.0% and profit rose 0.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is UFP Technologies, Inc. in?
Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +44.4% at its peak to +9.1% but is still expanding, ROCE slipping at 13.9%. The read comes from the last 12 quarters of growth (revenue growth +9.1% latest, profit growth +14.3% latest, eps growth +7.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is UFP Technologies, Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 5 of stage 2), trading +48.0% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is UFP Technologies, Inc. beating the market?
On recent form, yes — UFP Technologies, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 9 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +1,343% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.
Will UFP Technologies, Inc.'s stock price go up?
This page publishes no price forecast for UFP Technologies, Inc. What it measures instead: the stock price is $335, the price is in a confirmed uptrend 5 weeks in. Its P/E of 36.2× sits at the 82nd percentile of its own 4-year range. — as of 5 August 2026.
Is the market betting against UFP Technologies, Inc.?
Yes — short interest is 16.7% of UFP Technologies, Inc.'s tradable float, about 5.5 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does UFP Technologies, Inc. have too much debt?
No — UFP Technologies, Inc.'s debt-to-equity is 0.25. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.
What is UFP Technologies, Inc.'s capex?
UFP Technologies, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is UFP Technologies, Inc.'s cash flow?
UFP Technologies, Inc. generated $0.1 B of operating cash flow in FY25 and $0.1 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is UFP Technologies, Inc.'s profit real cash?
Yes — over the last 3 fiscal years, 118% of UFP Technologies, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.1 B against reported profit of $0.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is UFP Technologies, Inc.?
On the balance sheet, the Z-score reads 6.80 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is UFP Technologies, Inc. in its business cycle?
UFP Technologies, Inc.'s FY25 operating margin was 15.0%, against a 5-year band of 9.5%–17.1%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 13.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the UFP Technologies, Inc. story?
The sharpest disagreement: the price moved +47.8% in a year while annual EPS moved +15.4% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is UFP Technologies, Inc. a stock worth studying right now?
This is not investment advice. The machine read: UFP Technologies, Inc.'s price has outrun its earnings. +47.8% in a year against EPS +15.4% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.